Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokerages have set a twelve-month consensus target price of $25.50 for the company, according to Zacks. Zacks has also given Assembly Biosciences an industry rank of 246 out of 265 based on the ratings given to its competitors.

Several research firms have issued reports on ASMB. BidaskClub raised Assembly Biosciences from a “strong sell” rating to a “sell” rating in a report on Thursday, August 3rd. Zacks Investment Research lowered Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Finally, Chardan Capital began coverage on Assembly Biosciences in a report on Tuesday, May 30th. They set a “buy” rating and a $35.00 price target for the company.

Assembly Biosciences (NASDAQ ASMB) opened at 28.47 on Friday. The firm has a 50-day moving average price of $24.37 and a 200 day moving average price of $23.56. Assembly Biosciences has a 52 week low of $6.61 and a 52 week high of $28.73. The company’s market cap is $494.35 million.

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Assembly Biosciences by 21.2% during the second quarter. Vanguard Group Inc. now owns 610,916 shares of the biopharmaceutical company’s stock valued at $12,615,000 after purchasing an additional 107,065 shares during the period. State Street Corp bought a new stake in Assembly Biosciences during the second quarter valued at about $4,234,000. Northern Trust Corp grew its holdings in Assembly Biosciences by 221.2% during the second quarter. Northern Trust Corp now owns 195,321 shares of the biopharmaceutical company’s stock valued at $4,033,000 after purchasing an additional 134,513 shares during the period. JPMorgan Chase & Co. bought a new stake in Assembly Biosciences during the second quarter valued at about $3,426,000. Finally, Lyon Street Capital LLC grew its holdings in Assembly Biosciences by 352.6% during the second quarter. Lyon Street Capital LLC now owns 136,200 shares of the biopharmaceutical company’s stock valued at $2,813,000 after purchasing an additional 106,107 shares during the period. 72.27% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Zacks: Assembly Biosciences, Inc. (ASMB) Given $25.50 Average Target Price by Analysts” was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/09/08/zacks-assembly-biosciences-inc-asmb-given-25-50-average-target-price-by-analysts.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.